Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.61 |
| ▸ | ALKBH5 | Q6P6C2 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | KDM5C | P41229 | 3/20 | 0.61 |
| ▸ | KDM5A | P29375 | 3/20 | 0.61 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.61 |
| ▸ | KDM6B | O15054 | 2/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.61 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.61 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.61 |
| ▸ | TET3 | O43151 | 1/20 | 0.61 |
| ▸ | KDM4A | O75164 | 1/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ASPH | Q12797 | 1/20 | 0.61 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.61 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.61 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831092 | 1.00 | FTO (0.61) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL4353042 | 0.90 | ITGB3 (0.47) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL2713556 | 0.87 | KDM4E (0.61) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL5215154 | 0.87 | FTO (0.61) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL19439177 | 0.86 | PARP1 (0.43) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL2714272 | 0.84 | KDM4E (0.51) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL29831193 | 0.83 | SMYD3 (0.55) | BRD4ITGB3ITGA2B | |
| SCHEMBL13383551 | 0.83 | KDM4E (0.69) | KDM4EKDM5CKDM5AKDM6BKDM4C | |
| SCHEMBL29830791 | 0.81 | FTO (0.67) | FTOALKBH5KDM4EKDM5CKDM5A | |
| SCHEMBL19439262 | 0.81 | FTO (0.67) | FTOALKBH5KDM4EKDM5CKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| CN-108884070-A | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | 葛兰素史克知识产权第二有限公司 | 2018-11-23 | — | — | CN | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| CN-103249721-B | Arylamine Derivatives as TTX-S Blockers | 拉夸里亚创药株式会社 | 2016-10-12 | — | — | CN | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | FTO 1674/4885ALKBH5 2336/4885KDM4E 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.